Report Detail
Global Isocitrate Dehydrogenase Inhibitors Market Growth 2019-2024
- RnM3574923 |
- 05 July, 2019 |
- Global |
- 158 Pages |
- LPI(LP Information) |
- Other
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
According to this study, over the next five years the Isocitrate Dehydrogenase Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Isocitrate Dehydrogenase Inhibitors business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Isocitrate Dehydrogenase Inhibitors market by product type, application, key manufacturers and key regions and countries.
This study considers the Isocitrate Dehydrogenase Inhibitors value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Isocitrate Dehydrogenase Inhibitors consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Isocitrate Dehydrogenase Inhibitors market by identifying its various subsegments.
Focuses on the key global Isocitrate Dehydrogenase Inhibitors manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Isocitrate Dehydrogenase Inhibitors with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Isocitrate Dehydrogenase Inhibitors submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Isocitrate Dehydrogenase Inhibitors Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Isocitrate Dehydrogenase Inhibitors Consumption 2014-2024
- 2.1.2 Isocitrate Dehydrogenase Inhibitors Consumption CAGR by Region
- 2.2 Isocitrate Dehydrogenase Inhibitors Segment by Type
- 2.2.1 IDH1 Mutant Medullary Malignant Tumor
- 2.2.2 IDH2 Mutant Medullary Malignant Tumor
- 2.2.3 Others
- 2.3 Isocitrate Dehydrogenase Inhibitors Consumption by Type
- 2.3.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Isocitrate Dehydrogenase Inhibitors Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Isocitrate Dehydrogenase Inhibitors Sale Price by Type (2014-2019)
- 2.4 Isocitrate Dehydrogenase Inhibitors Segment by Application
- 2.4.1 DH Inhibitor
- 2.4.2 FLT3 Inhibitor
- 2.4.3 Hedgehog Pathway Inhibitor
- 2.4.4 Others
- 2.5 Isocitrate Dehydrogenase Inhibitors Consumption by Application
- 2.5.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Isocitrate Dehydrogenase Inhibitors Value and Market Share by Application (2014-2019)
- 2.5.3 Global Isocitrate Dehydrogenase Inhibitors Sale Price by Application (2014-2019)
3 Global Isocitrate Dehydrogenase Inhibitors by Manufacturers
- 3.1 Global Isocitrate Dehydrogenase Inhibitors Sales Market Share by Manufacturers
- 3.1.1 Global Isocitrate Dehydrogenase Inhibitors Sales by Manufacturers (2017-2019)
- 3.1.2 Global Isocitrate Dehydrogenase Inhibitors Sales Market Share by Manufacturers (2017-2019)
- 3.2 Global Isocitrate Dehydrogenase Inhibitors Revenue Market Share by Manufacturers
- 3.2.1 Global Isocitrate Dehydrogenase Inhibitors Revenue by Manufacturers (2017-2019)
- 3.2.2 Global Isocitrate Dehydrogenase Inhibitors Revenue Market Share by Manufacturers (2017-2019)
- 3.3 Global Isocitrate Dehydrogenase Inhibitors Sale Price by Manufacturers
- 3.4 Global Isocitrate Dehydrogenase Inhibitors Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
- 3.4.1 Global Isocitrate Dehydrogenase Inhibitors Manufacturing Base Distribution and Sales Area by Manufacturers
- 3.4.2 Players Isocitrate Dehydrogenase Inhibitors Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Isocitrate Dehydrogenase Inhibitors by Regions
- 4.1 Isocitrate Dehydrogenase Inhibitors by Regions
- 4.1.1 Global Isocitrate Dehydrogenase Inhibitors Consumption by Regions
- 4.1.2 Global Isocitrate Dehydrogenase Inhibitors Value by Regions
- 4.2 Americas Isocitrate Dehydrogenase Inhibitors Consumption Growth
- 4.3 APAC Isocitrate Dehydrogenase Inhibitors Consumption Growth
- 4.4 Europe Isocitrate Dehydrogenase Inhibitors Consumption Growth
- 4.5 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption Growth
5 Americas
- 5.1 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Countries
- 5.1.1 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
- 5.1.2 Americas Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
- 5.2 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Type
- 5.3 Americas Isocitrate Dehydrogenase Inhibitors Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Countries
- 6.1.1 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
- 6.1.2 APAC Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
- 6.2 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Type
- 6.3 APAC Isocitrate Dehydrogenase Inhibitors Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Isocitrate Dehydrogenase Inhibitors by Countries
- 7.1.1 Europe Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
- 7.1.2 Europe Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
- 7.2 Europe Isocitrate Dehydrogenase Inhibitors Consumption by Type
- 7.3 Europe Isocitrate Dehydrogenase Inhibitors Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors by Countries
- 8.1.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Value by Countries (2014-2019)
- 8.2 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption by Type
- 8.3 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
- 10.2 Isocitrate Dehydrogenase Inhibitors Distributors
- 10.3 Isocitrate Dehydrogenase Inhibitors Customer
11 Global Isocitrate Dehydrogenase Inhibitors Market Forecast
- 11.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Forecast (2019-2024)
- 11.2 Global Isocitrate Dehydrogenase Inhibitors Forecast by Regions
- 11.2.1 Global Isocitrate Dehydrogenase Inhibitors Forecast by Regions (2019-2024)
- 11.2.2 Global Isocitrate Dehydrogenase Inhibitors Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Isocitrate Dehydrogenase Inhibitors Forecast by Type
- 11.8 Global Isocitrate Dehydrogenase Inhibitors Forecast by Application
12 Key Players Analysis
- 12.1 AGIOS
- 12.1.1 Company Details
- 12.1.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.1.3 AGIOS Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.1.4 Main Business Overview
- 12.1.5 AGIOS News
- 12.2 Aslan Pharmaceuticals
- 12.2.1 Company Details
- 12.2.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.2.3 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.2.4 Main Business Overview
- 12.2.5 Aslan Pharmaceuticals News
- 12.3 Bayer
- 12.3.1 Company Details
- 12.3.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.3.3 Bayer Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.3.4 Main Business Overview
- 12.3.5 Bayer News
- 12.4 Beigene
- 12.4.1 Company Details
- 12.4.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.4.3 Beigene Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.4.4 Main Business Overview
- 12.4.5 Beigene News
- 12.5 Bristol-Myers Squibb
- 12.5.1 Company Details
- 12.5.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.5.3 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.5.4 Main Business Overview
- 12.5.5 Bristol-Myers Squibb News
- 12.6 Celgene
- 12.6.1 Company Details
- 12.6.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.6.3 Celgene Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.6.4 Main Business Overview
- 12.6.5 Celgene News
- 12.7 Daiichi Sankyo
- 12.7.1 Company Details
- 12.7.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.7.3 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.7.4 Main Business Overview
- 12.7.5 Daiichi Sankyo News
- 12.8 Philogen S.p.A.
- 12.8.1 Company Details
- 12.8.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.8.3 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.8.4 Main Business Overview
- 12.8.5 Philogen S.p.A. News
- 12.9 Tesaro
- 12.9.1 Company Details
- 12.9.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.9.3 Tesaro Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.9.4 Main Business Overview
- 12.9.5 Tesaro News
- 12.10 Tragara/Adastra
- 12.10.1 Company Details
- 12.10.2 Isocitrate Dehydrogenase Inhibitors Product Offered
- 12.10.3 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.10.4 Main Business Overview
- 12.10.5 Tragara/Adastra News
- 12.11 Tocagen
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Isocitrate Dehydrogenase Inhibitors. Industry analysis & Market Report on Isocitrate Dehydrogenase Inhibitors is a syndicated market report, published as Global Isocitrate Dehydrogenase Inhibitors Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Isocitrate Dehydrogenase Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
